| Analysis | Metabolite Name | Measured Value | Units | Group | TIMEPOINT |
|---|---|---|---|---|---|
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 0.4055 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 0.4461 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 0.4590 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 0.4972 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 0.5014 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 0.5315 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 0.5574 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 0.5703 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 0.6000 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 0.6208 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 0.6220 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 0.6227 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 0.6336 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 0.6433 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 0.6605 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 0.6706 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 0.6725 | scaled units | Placebo | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 0.6736 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 0.6956 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 0.7093 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 0.7117 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 0.7139 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 0.7146 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 0.7174 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 0.7191 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 0.7257 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 0.7323 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 0.7422 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 0.7550 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 0.7656 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 0.7675 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 0.7687 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 0.7717 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 0.7752 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 0.7771 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 0.7794 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 0.7877 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 0.7947 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 0.7968 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 0.8085 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 0.8191 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 0.8239 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 0.8326 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 0.8410 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 0.8411 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 0.8439 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 0.8467 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 0.8517 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 0.8540 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 0.8579 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 0.8604 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 0.8637 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 0.8646 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 0.8706 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 0.8745 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 0.8746 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 0.8777 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 0.8804 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 0.8820 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 0.8849 | scaled units | Placebo | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 0.8902 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 0.8921 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 0.8934 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 0.9013 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 0.9059 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 0.9075 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 0.9081 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 0.9100 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 0.9115 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 0.9123 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 0.9157 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 0.9277 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 0.9314 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 0.9339 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 0.9396 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 0.9413 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 0.9506 | scaled units | Placebo | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 0.9522 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 0.9529 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 0.9568 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 0.9598 | scaled units | Placebo | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 0.9599 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 0.9611 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 0.9724 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 0.9740 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 0.9820 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 0.9850 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 0.9852 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 0.9891 | scaled units | Placebo | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 0.9904 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 0.9958 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 0.9969 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 0.9973 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 1.0000 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 1.0027 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 1.0247 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 1.0287 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 1.0293 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 1.0438 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 1.0481 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 1.0494 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 1.0597 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 1.0633 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 1.0636 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 1.0651 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 1.0662 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 1.0724 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 1.0785 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 1.0856 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 1.0902 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 1.0952 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 1.0987 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 1.1003 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 1.1024 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 1.1042 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 1.1052 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 1.1059 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 1.1066 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 1.1127 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 1.1161 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 1.1196 | scaled units | Placebo | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 1.1233 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 1.1262 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 1.1306 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 1.1328 | scaled units | Placebo | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 1.1465 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 1.1491 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 1.1521 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 1.1566 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 1.1689 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 1.1805 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 1.1828 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 1.1880 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 1.1890 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 1.1978 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 1.2060 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 1.2158 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 1.2180 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 1.2232 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 1.2468 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 1.2554 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 1.2733 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 1.2766 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 1.2851 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 1.3052 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 1.3097 | scaled units | Placebo | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 1.3106 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 1.3145 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 1.3152 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 1.3213 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 1.3790 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 1.3876 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 1.3916 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 1.3988 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 1.4001 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 1.4452 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 1.4465 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 1.4560 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 1.4773 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 1.4955 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 1.5646 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 1.5874 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 1.5988 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 1.6088 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 1.6174 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 1.6709 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 1.6758 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 1.6806 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 1.6889 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 1.6909 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 1.7444 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 1.7925 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 1.8089 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 1.8233 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 1.8319 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 1.8375 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 1.8936 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 1.9785 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 1.9893 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 2.0133 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 2.0186 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 2.0390 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 2.0972 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 2.1590 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 2.2938 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 2.3743 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | stearate (18:0) | 2.4195 | scaled units | High-Dose | +47HR POST INFUSION |
- UCSD Metabolomics Workbench, a resource sponsored by the Common Fund of the National Institutes of Health
|